10H-phenothiazine 5-oxide is a chemical compound that is structurally related to phenothiazine, a known antipsychotic drug. However, 10H-phenothiazine 5-oxide itself is not a drug.
Here's why it is important for research:
* **Precursor to Drugs:** It serves as a valuable synthetic precursor to various pharmacologically active compounds, including:
* **Antipsychotics:** Phenothiazine derivatives, like chlorpromazine and thioridazine, are widely used in the treatment of schizophrenia and other mental health disorders. 10H-phenothiazine 5-oxide can be used to synthesize these drugs.
* **Antihistamines:** Some derivatives are used in antihistamine medications for treating allergies.
* **Antiparasitic agents:** Certain derivatives are used in veterinary medicine to treat parasitic infections.
* **Biological Studies:** 10H-phenothiazine 5-oxide itself is not a drug, but it is used in research studies to:
* **Study the mechanism of action of phenothiazine derivatives:** By studying its interactions with biological systems, researchers can gain insights into how these drugs work.
* **Develop new drugs:** It can serve as a starting point for the development of new and improved drugs with similar pharmacological properties.
* **Explore its own potential biological activity:** While not currently used clinically, it is being investigated for potential therapeutic applications in different areas.
**Overall, 10H-phenothiazine 5-oxide is a valuable tool for research in drug development, biological studies, and the understanding of how phenothiazine derivatives work.** It is important to note that this compound is not used clinically itself, but rather as a starting point for further development.
| ID Source | ID |
|---|---|
| PubMed CID | 71014 |
| CHEMBL ID | 1396515 |
| CHEBI ID | 125466 |
| SCHEMBL ID | 342511 |
| Synonym |
|---|
| 1207-71-2 |
| phenothiazine s-oxide |
| phenothiazine 5-oxide |
| nsc-3554 |
| usaf do-16 |
| nsc3554 |
| nsc 3554 |
| brn 0152295 |
| phenothiazine-5-oxide |
| ai3-17437 |
| smr000841349 |
| MLS001242794 |
| 10h-phenothiazine 5-oxide , |
| 10h-phenothiazine, 5-oxide |
| phenothiazine, 5-oxide |
| CHEBI:125466 |
| AKOS000281841 |
| sr-01000852665 |
| SR-01000852665-2 , |
| STK802590 |
| NCGC00247391-01 |
| 4-27-00-01215 (beilstein handbook reference) |
| 10h-phenothiazine,5-oxide |
| HMS2201K15 |
| HMS3341B02 |
| SCHEMBL342511 |
| DSAFSORWJPSMQS-UHFFFAOYSA-N |
| cid_71014 |
| bdbm65852 |
| CHEMBL1396515 |
| Q27216086 |
| DTXSID0074471 |
| mfcd00053824 |
| AT27299 |
| BS-50659 |
| BAA20771 |
| 10h-5lambda4-phenothiazin-5-one |
| EN300-309225 |
| 10h-5|e?-phenothiazin-5-one |
| 10h-phenothiazine5-oxide |
| 8SVJ4R3Y3D |
| Z1509140237 |
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 67.9K protein | Vaccinia virus | Potency | 2.2387 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| NADPH oxidase 1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0440 | 1.2609 | 5.5000 | AID2538 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||